Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Quantum BioPharma Ltd (QNTM) is a biopharmaceutical innovator developing therapies for neurodegenerative, neuropsychiatric, and inflammatory disorders. This page aggregates official news and press releases about the company’s clinical advancements, strategic investments, and market-related developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and strategic financial decisions, including partnerships or legal initiatives impacting shareholder value. The curated content spans research breakthroughs, intellectual property updates, and balanced coverage of both pharmaceutical R&D and complementary investment activities.
All content is sourced directly from company communications to ensure accuracy. Visitors can expect coverage of FDA trial phases, compound licensing deals, and portfolio management decisions from Quantum BioPharma’s dual operational segments. Bookmark this page for efficient tracking of material events affecting QNTM’s trajectory in the biotech sector.
Quantum BioPharma (NASDAQ: QNTM) has partnered with Massachusetts General Hospital (MGH) for a joint clinical study to validate a novel PET imaging technique for monitoring myelin integrity and demyelination in multiple sclerosis (MS) patients.
The study, led by Dr. Pedro Brugarolas and co-investigated by Dr. Eric Klawiter, will evaluate [18F]3F4AP PET scans alongside MRI scans in both progressive and relapsing-remitting MS forms. Previous studies in rodents and monkeys showed [18F]3F4AP's high sensitivity to demyelinated lesions, suggesting its potential as a biomarker for monitoring demyelination changes in response to MS treatments.
This PET imaging technique, using a radiolabeled form of dalfampridine, aims to complement MRI by providing ultra-sensitive and quantitative demyelination assessment. The research is particularly relevant to Quantum's Lucid-MS clinical development program, which has demonstrated myelin sheath protection in animal models.
Quantum BioPharma (NASDAQ: QNTM) has successfully closed the final tranche of its previously announced financing, raising $2.42 million in Debenture Units. This completion brings the total financing to $5 million, following amendments made on January 20, 2025, and improved terms announced on March 7, 2025.
The funds will be allocated to advance research and development of drug candidates, commercialization efforts, and general working capital. The company projects these funds will sustain operations until at least Q1 2027. Additionally, Quantum has initiated the development of rekvry™, a new alcohol misuse treatment designed for emergency and hospital settings, aimed at reducing healthcare costs and resource burden.
Quantum BioPharma (NASDAQ: QNTM) has announced the renewal of two service contracts. The company has extended its agreement with King Tide Media for a one-month term starting April 1, 2025, at a cost of US$15,000. Additionally, they have renewed services with IR Agency for a 60-day period beginning April 1, 2025, for US$50,000.
Quantum BioPharma (NASDAQ:QNTM) has reported strong financial improvements for Q4 and full year 2024. The company's cash position strengthened to $12.1M USD, up from $11.1M in 2023. Operating expenses decreased by 32% to $16.1M, while net loss improved by 18% to $14.9M compared to 2023.
Key developments include:
- Completion of unbuzzd™ clinical trial showing 40% faster reduction in Blood Alcohol Concentration
- Successful Phase 1 trial of Multiple Sclerosis drug Lucid-21-302
- Material Uncertainty Related to Going Concern removed with sufficient working capital through January 2027
- Strategic purchase of $3.5M in Bitcoin and cryptocurrencies
- Dual listing on Upstream exchange
The company's licensee, Celly Nutrition, is exploring an IPO and has secured distribution agreements in Puerto Rico, Caribbean, and parts of Central and South America for unbuzzd.
Quantum BioPharma (NASDAQ: QNTM) reported strong financial improvements for FY2024, removing Material Uncertainty Related to Going Concern. Cash position strengthened to $12.1M USD (up from $11.1M in 2023), with operating expenses reduced by 32% to $16.1M USD.
Key highlights include:
- Net loss improved 18% to $14.9M USD
- Net cash used in operations decreased 36% to $6.9M USD
- Successfully completed clinical trials for unbuzzd™ alcohol detoxification beverage, showing 40% faster BAC reduction
- Completed Phase 1 trial for Multiple Sclerosis drug Lucid-21-302, demonstrating safety and tolerability
- Expanded distribution network through FUSION Distribution Group for Caribbean markets
- Invested $3.5M in cryptocurrencies and dual-listed on Upstream exchange
Quantum BioPharma (NASDAQ: QNTM) has announced the appointment of Terry Lynch to its Board of Directors, replacing Dr. Sanjiv Chopra who will continue as an advisor. Lynch, known for founding Save Canadian Mining, brings extensive experience in fighting stock market manipulation and naked short selling.
Lynch currently serves as CEO of Power Metallic Mines, which recently secured a $50 million financing. He is also a co-founder of Cardiol Therapeutics and consultant to bionxt solutions. The company has granted Lynch 50,000 stock options at C$9.90 per Class B Share, expiring March 26, 2027.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition has launched new unbuzzd™ On-the-Go Powder Stick Packs in 8-pack display boxes for U.S. retail distribution. unbuzzd™ is a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.
The new format features TSA-compliant, pocket-sized powder sticks available in 3-pack, 8-pack, and 18-pack options, targeting convenience, liquor, and drug stores. The product is available on amazon.com and unbuzzd.com. Quantum BioPharma owns 25.71% of Celly Nutrition and receives a 7% royalty on unbuzzd™ sales until reaching $250 million, after which it drops to 3% perpetually.
The company retains full rights to develop similar products for pharmaceutical and medical uses. The launch targets the estimated $2.1 billion global hangover cure products market, supported by recent clinical trials proving the product's effectiveness in reducing blood alcohol concentration.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency portfolio with an additional USD $1,500,000 investment in Bitcoin (BTC) and other cryptocurrencies, following Board approval. This strategic move brings the company's total crypto investment to USD $3,500,000.
The company will continue accepting future financings and transactions in cryptocurrency, viewing it as a potential hedge against the dollar and an opportunity for shareholder returns. All crypto assets are held with a compliant custodian, and transactions adhere to financial and audit regulations. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions.
Quantum BioPharma (NASDAQ: QNTM) has successfully completed its Phase 1 Multiple Ascending Dose clinical trial for Lucid-21-302 (Lucid-MS), a novel multiple sclerosis drug. The Safety Review Committee confirmed the drug was well-tolerated with no safety concerns or serious adverse events reported.
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound featuring a unique mechanism of action. Preclinical models demonstrated its ability to stabilize the myelin sheath surrounding nerve fibers, potentially protecting against demyelination - a key characteristic of MS that leads to progressive disability.
Following this milestone, the company is preparing to advance to Phase 2 trials in MS patients, moving closer to their goals of drug approval and commercialization.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency holdings with an additional USD $1,000,000 investment in Bitcoin (BTC) and other cryptocurrencies, bringing its total crypto investment to USD $2,000,000. The investment, approved by the Board of Directors, is part of the company's strategic efforts to hedge against the Canadian dollar and potentially provide returns for shareholders.
The company has established infrastructure to accept cryptocurrency for financing and other transactions, with all digital assets being held by a fully compliant custodian. Quantum BioPharma emphasizes its commitment to maintaining compliance with financial and audit regulations while reserving the right to adjust its cryptocurrency holdings based on market conditions.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
